Formula extraction and query programs

Pre-packaged executable programs for Windows and Mac O

The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial

Background and Aim. Studies have shown an increasing number of type 2 diabetes (T2D) patients with concomitant obesity and hyperlipidemia syndromes, resulting from relevant metabolic disorders. However, there are few medications and therapies, which can thoroughly address these issues. Therefore, the current study evaluated the efficacy and safety of using JTTZ, a Chinese herbal formula, to treat T2D with obesity and hyperlipidemia. Methods. A total of 450 participants with T2D (HbA1c ≥ 7.0%; waist circumference ≥ 90 cm and 80 cm in males and females, resp.; and triglycerides (TG) ≥ 1.7 mmol/L) were randomly assigned, in equal proportions, to two groups in this multicenter randomized, positive-controlled, open-label trial. One group received JTTZ formula, and the other received metformin (MET) for 12 consecutive weeks. The primary efficacy outcomes were changes in HbA1c, TG, weight, and waist circumference. Adverse reactions and hypoglycemia were monitored. Results. HbA1c decreased by 0.75 ± 1.32% and 0.71 ± 1.2% in the JTTZ and MET groups, respectively, after 12 weeks of treatment. TG levels in the JTTZ and MET groups were reduced by 0.64 ± 2.37 mmol/L and 0.37 ± 2.18 mmol/L, respectively. Weight was decreased by 2.47 ± 2.71 kg in the JTTZ group and by 2.03 ± 2.36 kg in the MET group. JTTZ also appeared to alleviate insulin resistance and increase HOMA-β. In addition, symptoms were significantly relieved in participants in the JTTZ group compared to those in the MET group. One case of hypoglycemia was reported in the MET group. No severe adverse events were reported in either group. Conclusions. The JTTZ formula led to safe and significant improvements in the blood glucose, blood lipids, and weight levels; relieved symptoms; and enhanced β cell function for T2D patients with obesity and hyperlipidemia. The JTTZ formula has shown that it could potentially be developed as an alternative medicine for patients with T2D, particularly those who cannot tolerate metformin or other hypoglycemic drugs. This trial was registered with Clinicaltrials.gov NCT01471275

Highly Hydroxide-Conductive Nanostructured Solid Electrolyte via Predesigned Ionic Nanoaggregates

The creation of interconnected ionic nanoaggregates within solid electrolytes is a crucial yet challenging task for fabricating high-performance alkaline fuel cells. Herein, we present a facile and generic approach to embedding ionic nanoaggregates via predesigned hybrid core–shell nanoarchitecture within nonionic polymer membranes as follows: (i) synthesizing core–shell nanoparticles composed of SiO₂/densely quaternary ammonium-functionalized polystyrene. Because of the spatial confinement effect of the SiO₂ “core”, the abundant hydroxide-conducting groups are locally aggregated in the functionalized polystyrene “shell”, forming ionic nanoaggregates bearing intrinsic continuous ion channels; (ii) embedding these ionic nanoaggregates (20–70 wt %) into the polysulfone matrix to construct interconnected hydroxide-conducting channels. The chemical composition, physical morphology, amount, and distribution of the ionic nanoaggregates are facilely regulated, leading to highly connected ion channels with high effective ion mobility comparable to that of the state-of-the-art Nafion. The resulting membranes display strikingly high hydroxide conductivity (188.1 mS cm^–1 at 80 °C), which is one of the highest results to date. The membranes also exhibit good mechanical properties. The independent manipulation of the conduction function and nonconduction function by the ionic nanoaggregates and nonionic polymer matrix, respectively, opens a new avenue, free of microphase separation, for designing high-performance solid electrolytes for diverse application realms